Armata Pharmaceuticals Inc Dossier - Source-backed chat

Armata Pharmaceuticals Inc

ARMPNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.22

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.67Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $136.5M

Shares Outstanding 36.7M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Armata Pharmaceuticals is a late clinical-stage biotechnology company uniquely positioned to address the global crisis of antibiotic-resistant bacterial infections through its high-purity, pathogen-specific bacteriophage platform. Backed by majority owner Innoviva, Inc. (holding an 83.9% stake), Armata has secured critical financial runway via a $25 million secured term loan and extended credit maturities to June 1, 2027. The company's lead candidate, AP-SA02, has received FDA Fast Track and QIDP designations, and is poised to enter a Phase 3 superiority study in complicated S. aureus bacteremia in the second half of 2026. Despite going concern risks and heavy non-cash charges, the strategic backing of Innoviva and the high unmet medical need for phage therapeutics support a highly constructive outlook.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$17.50

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.0020%

Phase 3 trial initiation for AP-SA02 is delayed due to regulatory or manufacturing hurdles. Cash burn accelerates, and Innoviva declines to provide further non-dilutive or favorable debt financing, forcing highly dilutive equity raises or restructuring under going concern pressures.

Base CaseCentral scenario

$17.5050%

Matches the consensus mean

AP-SA02 enters Phase 3 clinical development in late 2026 with steady enrollment. Non-dilutive grant funding from the DoD/MTEC continues to offset R&D costs. Innoviva maintains its financial support, ensuring the company's cash runway extends through key clinical readouts. The stock trades closer to the consensus analyst target.

Bull CaseUpside scenario

$20.0030%

The Phase 3 trial for AP-SA02 initiates successfully in H2 2026 and demonstrates clear superiority over standard-of-care antibiotics in complicated S. aureus bacteremia. This triggers rapid regulatory approval, widespread clinical adoption, and potential licensing deals for other pipeline candidates (AP-PA02/AP-PA03). Innoviva continues to fully back the company financially, eliminating going concern risks.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong strategic and financial backing from majority shareholder Innoviva, Inc., which holds an 83.9% stake and recently provided a $25 million secured term loan.
Lead candidate AP-SA02 has received FDA Fast Track and QIDP designations, providing regulatory tailwinds ahead of its planned Phase 3 trial in H2 2026.
Proprietary, vertically integrated cGMP manufacturing capabilities that ensure high-purity phage cocktail production, a major competitive barrier in phage therapy.
Significant non-dilutive funding support from U.S. government agencies (DoD, MTEC) and the Cystic Fibrosis Foundation.

Key Investment Risks

Substantial going concern risk highlighted by independent auditors due to recurring operating losses and negative cash flows.
High concentration of ownership and control by Innoviva, limiting the influence of minority shareholders.
Clinical development risk inherent in late-stage trials for novel biologic modalities like bacteriophages.
Extremely thin analyst coverage and low stock liquidity, which can lead to high price volatility.

Thesis Invalidation Triggers

Failure to initiate the Phase 3 clinical trial of AP-SA02 in complicated S. aureus bacteremia by the end of 2026.
Withdrawal of financial support or refusal to extend credit maturities by Innoviva, Inc. beyond June 1, 2027.
Safety signals or lack of efficacy observed in ongoing clinical evaluations of the phage platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.